No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GMED240517P65000
- 3.80
- +0.80+26.67%
15min DelayClose May 8 15:59 ET
3.80High1.65Low
3.00Open3.00Pre Close85 Volume0 Open Interest65.00Strike Price20.76KTurnover41.85%IV-0.74%PremiumMay 17, 2024Expiry Date3.27Intrinsic Value100Multiplier8DDays to Expiry0.53Time Value100Contract SizeAmericanOptions Type-0.7715Delta0.0763Gamma16.57Leverage Ratio-0.0628Theta-0.0101Rho-12.79Eff Leverage0.0292Vega
Intraday
- 5D
- 1D
News
Globus Medical's Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
Top Gap Ups and Downs on Wednesday: UBER, BUD, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 227.32K in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 3,500 shares of its common stock on May 8, with a total market value of approximately $227.32K. Sou
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 1.3 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 20,000 shares of its common stock on May 8, with a total market value of approximately $1.3 million.
Globus Medical Shares Race Higher After Better-Than-Expected Q1 Results
Globus Medical, Inc. (NYSE:GMED) shares are trading higher Wednesday after the company posted better-than-expected first-quarter financial results and raised its fiscal year 2024 guidance. The Details
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
Health care stocks were declining Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.3%. The iShares Biotechnology ETF (IBB)
Comments
The company's CEO, Dan Scavilla, expressed confidence in Pfeil's ability to drive operational efficiency and deliver profitable growth, especially in light of the ongoing integration following their merger with NuVasive.
Press Release: Globus Medical Promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerGlobus Medical's superior earnings outlook is contributing to its high P/E, which shareholders are currently comfortable with, expecting not to face a threat to future earnings. The confidence in the future earnings performance supports the current share price.
Globus Medical's persisting issues impact its valuation and a drop in EPS may spark shareholder worry. The long-term share performance is lackluster, unsettling even potential contrarian investors seeking a turnaround.
Read more